Mr. James Lee reports

HEALWELL AI REACHES 47 PEER-REVIEWED PUBLICATIONS, STRENGTHENING ITS SCIENTIFIC MOAT FOR AI-POWERED REAL-WORLD CLINICAL EVIDENCE GENERATION

Healwell AI Inc. has continued the scientific validation of its Darwen AI (artificial intelligence) platform, with new research accepted for presentation at major international scientific conferences, including the European Crohn's and Colitis Organisation (ECCO) meeting, with publication in the Journal of Crohn's and Colitis. The study, conducted with the U.S. affiliate of a large pharmaceutical partner, demonstrated how AI-enriched Canadian patient support program data can generate real-world evidence to support U.S. Medical Affairs and market access initiatives, creating significant new commercial opportunities with existing pharmaceutical customers.

These new acceptances bring the total number of peer-reviewed publications validating Darwen AI to 47, spanning multiple disease areas and diverse patient populations.

In 2026, Healwell has already secured three additional conference acceptances in collaboration with leading global life sciences companies, highlighting the growing adoption of Darwen AI in real-world clinical research and evidence generation. The new clinical research studies examine:

• Treatment patterns of patients with inflammatory bowel disease;
• AI-enabled clinical decision support to improve Type 2 diabetes quality standards in primary care;
• Suicidal ideation and behaviour in patients with plaque psoriasis receiving systemic therapies.

Together, these studies demonstrate how Darwen AI can generate clinical insights from large-scale real-world health care data, supporting research, safety analysis and quality improvement initiatives.

Sacha Gera, Healwell's chief operating officer who oversees the company's AI division, commented: "The scientific team at Healwell continues to set the standard for clinically validated AI, producing peer-reviewed research that carries real weight in the global medical community. What is particularly exciting is seeing this work expand globally through collaborations with the U.S. affiliates of our existing pharmaceutical partners, extending the reach and impact of Darwen AI across new markets. Each publication generates new partnership inquiries, which generate new data access, which enables new publications, creating a compounding scientific and commercial moat that becomes harder to replicate with every study."

Unlocking real-world data from the electronic health record

Darwen AI is designed to unlock insights from the vast amount of unstructured clinical data embedded within electronic health records (EHRs), including physician notes, reports and diagnostic documentation. By transforming this previously inaccessible data into structured, research-ready insights, Darwen AI enables health care systems, researchers and life sciences companies to better understand disease patterns, treatment outcomes and patient populations in real-world clinical settings.

Healwell's strategy is centred on activating health care system data using its clinically validated Darwen AI engine while expanding the distribution of its AI capabilities through partnerships with health care providers, health systems and life sciences companies. Peer-reviewed validation plays a critical role in this strategy, creating true product differentiation in the marketplace. Each new publication strengthens Darwen AI's scientific credibility, expands its validation across additional disease states and clinical environments, and enables health care and life sciences organizations to make informed decisions about which AI partner best meets their needs. This growing body of evidence establishes a defensible foundation for broader adoption across health care systems, pharmaceutical research and population health initiatives.

Across 47 peer-reviewed publications and ethics-approved real-world evidence studies, Darwen AI has demonstrated the ability to analyze millions of clinical records while maintaining research-grade rigour. This growing validation portfolio reinforces the credibility of Healwell's technology within the global academic and life sciences research community.

Expanding validation across high-value disease areas

Research validating Darwen AI spans a broad range of therapeutic areas, demonstrating the platform's versatility across complex health care environments, including:

• Cancer and oncology;
• Cardiovascular disease;
• Chronic disease and internal medicine;
• Dermatology;
• Gastrointestinal diseases;
• Infectious diseases;
• Mental health;
• Ophthalmology;
• Rare diseases;
• Social determinants of health;
• Substance use and addiction.

These studies include diverse real-world patient populations across multiple ethnicities and socio-economic backgrounds, strengthening Darwen AI's applicability for population health management, real-world evidence generation and precision medicine initiatives.

By expanding validation across these disease areas, Healwell is increasing the clinical utility of its AI platform while creating new opportunities to support health care systems, academic researchers and global life sciences companies seeking to generate insights from real-world health care data. This growing body of scientific validation also helps build a long-term pipeline of commercial and research opportunities as health care organizations increasingly look to leverage real-world clinical data to improve outcomes and advance medical research.

James Lee, chief executive officer of Healwell, commented: "We are building the scientific foundation that will make Darwen the default AI layer for real-world evidence generation in global health care. Scientific validation is a critical component of that strategy. Each new peer-reviewed publication strengthens the credibility of Darwen AI and expands its validation across additional disease areas and clinical settings. With 47 peer-reviewed publications and growing, we believe our clinically validated AI will play an increasingly important role in helping health care systems and researchers unlock insights from real-world data, improve clinical decision making and ultimately deliver better patient outcomes."

About Healwell AI Inc.

Healwell is a health care artificial intelligence company focused on preventive care. Its mission is to improve health care and save lives through early identification and detection of disease. Using its own proprietary technology, the company is developing and commercializing advanced clinical decision support systems that can help health care providers detect rare and chronic diseases, improve efficiency of their practice, and ultimately help improve patient health outcomes. Healwell is executing a strategy centred on developing and acquiring technology and clinical sciences capabilities that complement the company's road map. Healwell is publicly traded on the Toronto Stock Exchange under the symbol AIDX and on the OTC (over-the-counter) exchange under the symbol HWAIF.

We seek Safe Harbor.